No Picture
News

Halozyme Reports First Quarter 2020 Results

– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]